Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2007-04-24
2007-04-24
Sullivan, Daniel M. (Department: 1636)
Chemistry: molecular biology and microbiology
Vector, per se
C514S04400A
Reexamination Certificate
active
09991721
ABSTRACT:
A composition of matter comprising a vaccinia virus expression vector with a negative thymidine kinase phenotype and a negative vaccinia virus growth factor phenotype.
REFERENCES:
patent: 5236838 (1993-08-01), Rasmussen et al.
patent: 5622835 (1997-04-01), Herlyn et al.
patent: 5739027 (1998-04-01), Kamb
patent: 5744133 (1998-04-01), Lathe et al.
patent: 5851991 (1998-12-01), Lee et al.
patent: 5942235 (1999-08-01), Paoletti
patent: 5962260 (1999-10-01), Sawamura et al.
patent: 5981714 (1999-11-01), Cheng et al.
patent: 6093700 (2000-07-01), Mastrangelo et al.
patent: 6103244 (2000-08-01), Dorner et al.
patent: 3411472 (1984-10-01), None
patent: 0 443 335 (1991-08-01), None
patent: 0 585 960 (1994-09-01), None
patent: 55026477 (1980-02-01), None
patent: 402065779 (1990-03-01), None
patent: WO 92/15672 (1992-09-01), None
patent: WO 94/16716 (1994-08-01), None
patent: WO 94/10575 (1994-11-01), None
patent: WO 95/31105 (1995-11-01), None
patent: WO 98/08394 (1998-05-01), None
Kaplan C. Vaccinia virus: a suitable vehicle for recombinant vaccines? Arch Virol. 1989;106(1-2):127-39.
Zhang et al. An enhanced green fluorescent protein allows sensitive detection of gene transfer in mammalian cells. Biochem Biophys Res Commun. Oct. 23, 1996;227(3):707-11.
UniProtKB/Swiss-Prot Database entry P04637, P53—HUMAN.
Advani, S. J., et al. (1999) Replication-competent, Nonneuroinvasive Genetically Engineered Herpes Virus Is Highly Effective in the Treatment of Therapy-resistant Experimental Human Tumors. Cancer Res. 59:2055-2058.
Beer, S. J., et al. (1998) Poly (lactic-glycolic) acid copolymer encapsulation of recombinant adenovirus reduces immunogenicity in vivo. Gene Ther. 5:740-746.
Buller, R. M. L., et al. (1988) Deletion of the Vaccinia Virus Growth Factor Gene Reduces Virus Virulence. J. Virol. 62(3):866-874.
Buller, R. M. L., et al. (1988) Cell Proliferative Response to Vaccinia Virus Is Mediated by VGF. Virology 164:182-192.
Buller, R. M., et al. (1985) Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 317:813-815.
Carroll, M. W. and Moss, B. (1997) Poxviruses as expression vectors. Curr. Opin. Biotechnol. 8:573-577.
Chakrabarti, S., et al. (1997) Compact, Synthetic, Vaccinia Virus Early/Late Promoter for Protein Expression. BioTechniques 23:1094-1097.
Chase, M., et al. (1998) An oncolytic viral mutant that delivers theCYP2B1transgene and augments cyclophosphamide chemotherapy. Nat. Biotech. 16:444-448.
Chillon, M., et al. (1998) Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro. Gene Ther. 5:995-1002.
Davison, A. J. and Moss, B. (1989) Structure of Vaccinia Virus Late Promoters. J. Mol. Biol. 210:771-784.
Davison, A. J. and Moss, B. (1989) Structure of Vaccinia Virus Early Promoters. J. Mol. Biol. 210:749-769.
Dmitriev, I., et al. (1998) An Adenovirus Vector with Genetically Modified Fibers Demonstrates Expanded Tropism via Utilization of a Coxsackievirus and Adenovirus Receptor-Independent Cell Entry Mechanism. J. Virol. 72(12):9706-9713, 1998.
Flexner, C., et al. (1990) Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2. Vaccine 8:17-21.
Galmiche, M. C., et al. (1997) Expression of a functional single chain antibody on the surface of extracellular enveloped vaccinia virus as a step towards selective tumour cell targeting. J. Gen. Virol. 78:3019-3027.
Gnant, M. F. X., et al. (1999) Systemic Administration of a Recombinant Vaccinia Virus Expressing the Cytosine Deaminase Gene and Subsequent Treatment with 5-Fluorocytosine Leads to Tumor-specific Gen Expression and Prolongation of Survival in Mice. Cancer Res. 59:3396-3403.
Gnant, M. F. X., et al. (1999) RegionalVersusSystemic Delivery of Recombinant Vaccinia Virus as Suicide Gene Therapy for Murine Liver Metastases. Ann. Surg. 230(3):352-361.
Goede, V., et al. (1998) Analysis of Blood Vessel Maturation Processes during Cyclic Ovarian Angiogenesis. Lab. Investig. 78(11):1385-1394.
Gurvich, E. B. and Vilesova, I. S. (1983) Vaccinia Virus in Postvaccinal Encephalitis. Acta. Virol. 27:154-159.
Heise, C., et al. (1997) ONYX-015, and E1B gene-attenuated adenovirus, causes tumor-specific cytollysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3(6):639-645.
Hodge, J. W., et al. (1994) Induction of Antitumor Immunity by Recombinant Vaccinia Viruses Expressing B7-1 or B7-2 Costimulatory Molecules. Cancer Res. 54:5552-5555.
Kantor, J., et al. (1992) Immunogenicity and Safety of a Recombinant Vaccinia Virus Vaccine Expressing the Carcinoembryonic Antigen Gene in a Nonhuman Primate. Cancer Res. 52:6917-6925.
Kaplan, E. L. and Meier, P. (1958) Nonparametric Estimation From Incomplete Observations. Am. Stat. Assoc. J. 53:457-481.
Karupiah, G., et al. (1990) Vaccinia virus-mediated damage of murine ovaries and protection by virus-expressed interleukin-2. Immunol. Cell Biol. 68:325-333.
Keane, J. T., et al. (1983) Progressive Vaccinia Associated With Combined Variable Immunodeficiency. Arch. Dermatol. 119:404-408.
Kim, C. J., et al. (1998) Use of Recombinant Proxviruses to Stimulate Anti-Melanoma T Cell Reactivity. Ann. Surg. Oncol. 5(1):64-76.
Kim, D. H., and McCormick, F. (1996) Replicating viruses as selective cancer therapeutics. Mol. Med. Today 2:519-527.
Kohn, S., et al. (1992) Pathways of Macromolecular Tracer Transport Across Venules and Small Veins. Lab. Investig. 67(5):596-607.
Lane, J. M. and Millar, J. D. (1971) Risks of Smallpox Vaccination Complications in the United States. Am. J. Epidemiol. 93(4):238-240.
Mantel, N. (1966) Evaluation of Survival Data and Two New Rank Order Statistics Arising in its Consideration. Cancer Chemother. Reps. 50(3):163-170.
Martuza, R. L., et al. (1991) Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant. Science 252:854-856, 1991.
Mastrangelo, M. J., et al. (2000) Intralesional Vaccinia/GM-CSF Recombinant Virus in the Treatment of Metastatic Melanoma. Adv. Exp. Med. Biol. 465:391-400.
Mastrangelo, M. J. et al. (1998) Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. 6(5):409-422.
McAneny, D., et al. (1996) Results of a Phase I Trial of a Recombinant Vaccinia Virus That Expresses Carcinoembryonic Antigen in Patients with Advanced Colorectal Cancer. Ann. Surg. Oncol. 3(5):495-500.
McCart, J. A., et al. (2001) Systemic Cancer therapy with a Tumor-selective Vaccinia Virus Mutant Lacking Thymidine Kinase and Vaccinia Growth Factor Genes. Cancer Res. 61:8751-8757.
McCart, J. A., et al. (2000) Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression. Gene Ther. 7:1217-1223.
Meko, J. B., et al. (1995) High Cytokine Production and Effective Antitumor Activity of a Recombinant Vaccinia Virus Encoding Murine Interleukin 12. Cancer Res. 55:4765-4770.
Moss, B. (1996) Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. PNAS USA 93:11341-11348.
Mukherjee, S., et al. (2000) Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: Persistent transgene expression despite antibody generation. Cancer Gene Ther. 7(5):663-670.
O'Reilly, M. S., et al. (1997) Endostatin: an Endogenous Inhibitor of Angiogenesis and Tumor Growth. Cell 88:277-285.
Overwijk, W., et al. (1999)Vaccination with a recombinant vaccinia virus encoding a “self” antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement of CD4+ T lymphocytes. PNAS USA 96:2982-2987.
Palumbo, G. J., et al. (1998) A Replication Competent Recombinant Vaccinia Vector Expressing HSV-TK for the Treatment of Tumorsin Vivo. Am. Soc. Gene Ther. 1:169a.
Park, B. J., et al. (1999) Augmentation of Melanoma-Specific Gene Expression Using a Tandem Melanocyte-Specific Enhancer Results in Increased Cytotoxicity of the Purine Nucleoside Phosphorylase Gene in Melanoma. Hum
Bartlett David L.
McCart J. Andrea
Moss Bernard
Klarquist & Sparkman, LLP
Sullivan Daniel M.
United States of America as represented by the Secretary of the
LandOfFree
Combined growth factor-deleted and thymidine kinase-deleted... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combined growth factor-deleted and thymidine kinase-deleted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combined growth factor-deleted and thymidine kinase-deleted... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3731052